Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.
Charles Schwab Investment Management Inc. reduced its stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 16.3% in the 4th ...
Analysts at Chardan Capital reduced their FY2025 earnings estimates for shares of REGENXBIO in a research report issued to ...
Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug ...
Investors in REGENXBIO Inc. (NASDAQ:RGNX) need to pay close attention to the stock based on moves in the options market lately.
At close: March 28 at 4:00:00 PM EDT ...
Copyright © 2025 MarketWatch, Inc. All rights reserved.
6d
U.S. stock futures were lower this morning, with the Dow futures falling around 50 points on Wednesday. Shares of Chewy, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback